Dr. Sanne Holt is the Group Leader at our site in Leiden, The Netherlands. Her research focuses on efficacy and toxicity testing of novel drug therapies in human primary cell-based models. She previously worked as an investigator within the Cell and Gene Therapy Unit for GlaxoSmithKline, where she focused on the translational and safety aspects of T cell therapies.
Dr. Holt holds an MRes and PhD in medical and molecular genetics from King’s College London.